Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer

Rhea-AI Summary

Genetron Holdings Limited (Nasdaq: GTH) announced the release of 13 new research findings at the 21st World Conference on Lung Cancer (WCLC), occurring virtually from January 28 to 31. These studies focus on lung cancer characteristics in the Chinese population, including gene mutation and fusion patterns, immunotherapy markers, and bioinformatics models.

Noteworthy studies include the exploration of EGFR and JAK mutations, the mapping of NTRK1 fusions, and the optimization of early lung adenocarcinoma detection methods. These findings underscore Genetron’s capabilities in advancing personalized lung cancer treatment strategies.

Positive

• Thirteen new studies on lung cancer characteristics highlight Genetron's expertise in genomics research.
• Research findings indicate potential for personalized treatment strategies based on mutation profiles.
• Study 3698 shows KMT2C/D mutations may improve immunotherapy outcomes for NSCLC patients.

Negative

• None.

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will release thirteen new research findings at the 21^st World Conference on Lung Cancer (WCLC), which will be held virtually from January 28 to 31. One of the research findings (Study 3713) was selected for a mini oral presentation.

Genetron Health joined hands with eight top Chinese hospitals to conduct in-depth analysis and research on a large-scale lung cancer cohort, leveraging the Genetron One-Step Seq Method and core products such as Onco Panscan^TM. The research has achieved key findings in gene mutation and fusion feature mapping, immunotherapy marker detection, bioinformatics analysis, etc., laying the groundwork for further exploration of lung cancer diagnosis, treatment and the design of treatment solutions.

Exploring the characteristics of gene mutation

Seven studies (#1766, #2150, #2226, #2007, #1780, #1452, #835) on EGFR mutations, JAK family gene mutations, FGFR1-4 mutations, KIT activating mutations, mTOR signaling pathway mutations, and IDH1/2 mutations, respectively, were conducted to explore their mutation patterns and distribution characteristics in Chinese lung cancer patients, and to search for drug-resistant targets and effective solutions.

Exploring the characteristics of gene fusion

Study 3609 involved an in-depth analysis of 10 gene fusion patterns and distributions in the Chinese lung cancer population, as well as their co-occurrences with other driver mutations, in order to construct initial gene fusion mapping. Study 3601 focused on the prevalence and clinical benefit ratio of NTRK1 rare fusion in the Chinese lung cancer population.

Detecting immunotherapy markers

Study 3698 demonstrated the usage of KMT2C/D gene mutations as a positive predictor of the efficacy of non-small cell lung cancer (NSCLC) immunotherapy, indicating that patients with such gene mutations may benefit from immunotherapy. Study 3713 focused on the differences amongst DDR (DNA Damage Response) signaling pathway-related gene mutations in NSCLC and small cell lung cancer (SCLC), supporting the research of immunotherapy in the two patient groups.

Optimizing bioinformatics models

Based on six CpG sites, Study 2231 developed a random forest classification model, a new type of bioinformatics model, to distinguish early lung adenocarcinoma from benign nodules.

Rare case research

Study 3630 used Genetron's One-Step Seq patented technology (Chinese Invention Patent No. ZL 201710218529.4) in the detection of a very rare patient with dual ROS1 fusion lung adenocarcinoma in a cohort of 180 people, demonstrating an efficacy greater than those of common diagnostic methods. In addition, the study noted the patient's positive reaction to crizotinib, which indicates a direction for future research on the mechanism of this rare phenomenon.

“The thirteen research findings we are releasing at the WCLC, which focus on the characteristics of the Chinese lung cancer population, have made discoveries in multiple dimensions and demonstrated Genetron Health’s strong capabilities in the fundamental research of lung cancer genomics,” said Dr. Hai Yan, Co-founder and Chief Scientific Officer of Genetron Health. “The research findings regarding EGFR, JAK, FGFR and other mutation patterns, and drug resistance studies can enhance the development of more diverse and personalized medication strategies for patients. Gene fusion mapping can guide the design of more advanced and rich diagnostic products. The discovery of KMT2C/D mutations indicates more possibilities for lung cancer patients to benefit from immunotherapy treatments. In addition, the rare cases detected through Genetron Health’s patented research technology will draw more attention to and promote further research on relevant cancer diagnosis and treatment."

 

ABSTRACT NUMBER	ABSTRACT TITLE
2226	Identification of FGFR Mutations in Chinese Lung Cancer Patients by Next-Generation Sequencing
3609	Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis
2150	Next generation sequencing reveals the genetic landscape of JAK family in Chinese lung cancer patients
1766	Comprehensive investigation of uncommon EGFR mutations in 14,429 Chinese lung cancer patients
1780	Next-generation sequencing guided the gene mutations associated with mTOR-inhibitors in Chinese lung cancer patients
3601	The prevalence of NTRK1 fusion in a Chinese lung cancer cohort
3630	A recommended one-step targeted sequencing technology for identification of a dual CD74-ROS1 in NSCLC
2231	Identification of DNA methylation markers to distinguish early-stage lung adenocarcinomas from benign pulmonary nodules
3713	DNA damage response gene alterations and their association with tumor mutation burden and response to immunotherapy in NSCLC and SCLC
3698	Association of KMT2C/D mutations with tumor mutation burden and response to immune checkpoint inhibitors in NSCLC
2007	Molecular Alterations of KIT Oncogene in a Large Cohort of Chinese Pan-Lung Cancer Patients
835	Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC
1452	A Large-Scale Survey of IDH Mutation in Chinese Patients With NSCLC

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding research results, genomics exploration, bioinformatics model construction and optimization, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005381/en/

FAQ

What new research findings did Genetron Holdings Limited release at the WCLC?

Genetron released thirteen new research findings at the 21st World Conference on Lung Cancer, focusing on lung cancer genomics and treatment options.

What specific studies were highlighted by Genetron at the 2023 World Conference on Lung Cancer?

Key studies include those on gene mutation patterns, gene fusion mapping, and immunotherapy markers related to lung cancer.

How do the new findings impact immunotherapy for lung cancer patients?

The findings suggest that KMT2C/D mutations may serve as positive predictors for the efficacy of immunotherapy in NSCLC patients.

What is the significance of Genetron's research on gene mutations in lung cancer?

Genetron's research identifies drug-resistant targets and informs more diverse and personalized medication strategies for lung cancer treatment.

When was the WCLC held where Genetron presented its research?

The 21st World Conference on Lung Cancer took place virtually from January 28 to 31, 2023.